Is APHA trading in a massive descending triangle?I hope not, but hope isn't a good investment strategy, and with the negative sentiment in the cannabis industry I wouldn't be surprised to see this get down to 1.10. This could be a giant bull flag as well, but I don't know were the buy pressure will come from in this sketchy market?
Time will tell per usual.
Healthcare
Harrow may bounce on lawsuit newsBack in May, a jury ruled in Harrow Health's favor in a lawsuit that Allergan filed against Harrow for intellectual property infringement. Allergan has been appealing the ruling, but today the two companies jointly filed an 8k form indicating that they had jointly dismissed all pending appeals and exchanged no money. In other words, Harrow got off scot-free and will no longer incur legal fees related to the case. This is great news, so it's surprising that the stock is down, especially when the market as a whole is up. Perhaps Harrow will get a boost if some news agencies pick up the story. In the meantime, Harrow is approaching support at about $5. I picked up a few shares at $5.25 and will look to buy more at $5.
Harrow Health has a 9.4/10 Equity StarMine Summary Score and is rated undervalued (73/100) by S&P Capital IQ.
$VIVE Classic "Cursed After Reversed" Or Can It ReVIVE Itself?VIVE seems like it can't get out of its own way. Great gap up in the morning but yet again, another red close. Even after reversing, shares are back at penny stock levels. So is it doomed to repeat history or can it find a new bottom? I don't know if anyone really knows for sure just yet.
"Viveve’s stock price had a terrible September, dropping more than 57%. However, its start to October is looked promising at the start. The healthcare penny stock gapped up over 25% during premarket hours on October 1st. In addition, the penny stock has already tripled its average trading volume. But as you see, VIVE stock has pulled back considerably from those premarket highs."*
*Quote Source: 5 Money Making Penny Stocks To Watch This Week
Most Recent News: Viveve Raises $6.76 million Through Completion of At-The-Market Equity Financing
ENGLEWOOD, CO / ACCESSWIRE / October 1, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced the completion of its at-the-market (ATM) offering of $6.76 million of shares of its common stock with Ladenburg Thalmann & Co. Inc. as the sales agent. The company sold 1,004,171 shares at a weighted average price of $6.73 per share (adjusting for a reverse stock split of Viveve common stock effected September 18, 2019) resulting in net proceeds of approximately $6.56 million to the company after deduction of sales commissions. As of September 30, 2019, the company had 1,469,589 shares outstanding.
About VIVE
Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates cryogen-cooled monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session.
News Source: finance.yahoo.com
Why Is KSHB Going Up While Most Pot Stocks Are Getting Slammed?KSHB has been one of just a fine few pot stock related names that has actually gone up. So what's the deal? The company’s stock price struggled throughout September, decreasing 60% on a massive drop during trading hours on September 26th. This was due to the company announcing a direct offering for shares at $1.75 per. This cannabis company is comprised of several industry-leading companies. This includes one of the largest producers of vaporizer products and packaging, Kush Supply Co. Furthermore, it owns Kush Energy which provides hydrocarbon gases and solvents to the cannabis sector.
"The direct offering was valued at $30.2 million and is expected to close relatively soon. Investors must have found this offering promising because today, on October 1st, the marijuana stock is up 11%. Could this lead to a strong and promising October for investors after that rough September?"*
*Quote Source: 5 Penny Stocks To Watch This Week
Stock: KSHB
A healthcare sector play without the political riskI posted the other day about how the healthcare sector would be a good defensive play in October but for the political risk faced by health insurers and pharmaceutical companies. Well, here's a company with great financials and none (or at least less) of that political risk. SMED is a medical waste disposal company, and its services would still be in demand even if the US passed a universal healthcare law.
SMED has an 8.8 Equity StarMine Summary Score and is rated "Undervalued" by the fundamental analysts at S&P Capital IQ. It's a little high in its RSI channel right now, but it still seems to be uptrending. I expect it will soon retest its recent highs at 4.46-4.48, and if it pushes above that level then it could get a nice breakout. SMED utterly destroyed analyst expectations on its last earnings report and has plenty of room to run.
UNH insider sales flash a warning sign ahead of earningsUnitedHealth Group has had an incredibly strong showing this year, and right now it's priced pretty attractively at oversold level on the hourly chart. On its daily chart it's at RSI 38, nearing oversold (RSI 30) but not quite there yet. It also hasn't yet tested its August low of 220.78 or its one-year lows of 208.07 and 216.84. I suspect we'll get a bounce tomorrow from the hourly oversold level, then fall some more to the 216-220 range. At that point we should be about oversold on the daily chart and should bounce into earnings on October 15.
The average analyst price target on UNH is about 299, implying about 33% upside from the current price. Analyst estimates of UNH earnings have held steady for the past month at 3.77, significantly better than 3.41 the same quarter last year. UNH has an 8.7/10 Equity Starmine Summary Score rating. So most signs are bullish. However, company director Richard Burke sold 10,000 shares last week. Other directors also recently sold thousands of shares. All this insider selling doesn't inspire confidence for good earnings this quarter. On that basis alone, I don't think I'd hold this for anything more than a pre-earnings bounce. On the other hand, insider sellers may be responding to political risk rather than to the company's financials.
The healthcare sector is expected to report good earnings this quarter, which could make it attractive as a defensive play in an earnings recession. Healthcare is a defensive sector that usually does well when the rest of the market is down. Right now healthcare stocks are cheap, which makes them even more attractive. However, with Elizabeth Warren leading the Democratic pack, UNH's share price may continue its breakdown. Health insurance and pharmaceutical companies are at particular risk from Warren's "Medicare for All" plan, and you may be able to chart healthcare stocks' performance from now until the election as a function of Warren's popularity in the polls.
CURE buy for the LONG (2+ years)Buying at ~53.37. taking profits at red line.
my fair value for this etf is $62 per share.
Will Kaya make Porinju Veliyath Right? - 70% Fall in 15 Months 1200 to 360... 70% Fall in 15 Months of Kaya Health Care. Any Guesses on what this will do for Porinju veliyath & Equity "Intelligence" ?
SAVA - Above MA's Possible 15% TargetCassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
SHORT INTEREST
1.64M 08/30/19
P/E Current
-2.07
P/E Ratio (with extraordinary items)
-5.00
Average Recommendation: BUY
Average Target Price: 3.00
Get High Returns: Long PsycheMedicscompany with a few decades of history, niche product/ market, remains fairly innovative
debt vs. cash +cash flow is net positive. low share count float
Buyout Target
CVS attempting rising wedge breakoutCVS has been testing the upper trend line of its rising wedge, which it has breached a couple times in the last two days. The last three days have also seen heavy call option buying activity. CVS has a very bullish 9.4/10 Equity StarMine rating, and it's rated as extremely undervalued by S&P Capital IQ.
Investors are betting, in part, that CVS will benefit from the bankruptcy of Fred's, a major competitor. CVS is also now going to be selling a CBD (cannabis) product from SocialCBD. Plus, CVS has big plans to open 50 HealthHUB stores, low-cost clinics that will leverage artificial intelligence as a diagnostic tool. This could help disrupt the cost bubble in the healthcare industry.
I don't know that the rising wedge will necessarily break today, but I do think that CVS should see continued strength in the coming year. This is a good long-term buy and hold.
Gonna Need A Bigger Boat CYHThe biotech sector is known for generating some of the most volatile names around and for good reason. When it comes to biotech and healthcare stocks, innovation is the focus.
" Healthcare penny stock Community Health Systems Inc. ( CYH ) is a healthcare company that buys and runs acute care hospitals in the US. The company operates an impressive 103 hospitals across 18 states, holding 17,000 beds. Ever since August 28th, CYH stock has been thriving. It is up over 82% since the 28th going from $1.82 to $3.48."
But between the divestiture of assets and this insider buying well below the current share price, what comes next? What catalyst can we look toward now?
"From August 27th to August 29th, more than $2 million was spent between Wayne Smith and Benjamin Fordham to pick up more than 1 million shares. The majority of these shares were bought by Smith at an average price between $1.84 and $2.18"
3 Penny Stocks On Robinhood To Watch This Week
pennystocks.com
J&J vs opioids (Johnson is winning)Fundamental analysis
In one of the first state opioid cases, an Oklahoma judge ruled against Johnson & Johnson, awarding the state $572 million, well below the over $17 billion the state was seeking in damages.
Meaning... out of the 17 billion, they lost only 3.36%, and they expect to appeal the case, probably lowering this amount.
Technical analysis
On a technical analysis, I still think the risk reward ratio is too small to enter a position now. But technicals are good (not great). So I am keeping this on my watchlist.
Bullish SharkLeap is looking to make another leap. Harmonic shark patterns leave more room for volatility trades and make for high reward scenario's when traded correctly.
As of today (09-04-2019), 84,220 of the 261,828 shares traded where short. This is equivalent to a sizable 32.17% short percent.
The technical's are now aligning with some key dates with a potential short squeeze on its way (assuming good data).
$LPTX is trading at the lower end of the long-term trading range.
Bullish harmonic shark pattern, look for profit taking and/ or chances to add at the 382 and 50 retracement levels to ride up to the top of the range.
Not only does this trade have massive upside potential for a swing trade, it is also showing confluence with Fibonacci time-cycles, fib-retracement and trend.
Tip of the day: Learning how to be disciplined is vital to trading volatility. Follow our trading team for ideas on how to stay more disciplined in biotech.
Disclosure: I have no position in LPTX. I may buy or sell in the next 72 hours. This is not a note to but or sell. Please do your homework before investing.
Several buy signals on UNHI've been watching UNH closely ever since its big guidance upgrade on the last earnings report. The stock chose that moment to start tanking, and it's been tanking ever since. Hopefully the market has now had enough of this down trend and is ready for the stock to recover.
Zacks, one of the best-performing analytics firms, upgraded UNH today to a buy. It's got an 8.3/10 Equity StarMine Summary score. UNH also flashed a buy signal a few days ago on the reverse RSI indicator, and it's in oversold territory on the daily stochastic. There's strong support from volume in the 220-228 range, so this is a good range to buy. Below 220, we could fall to 212 or 200.
DURECT CORP - NASDAQ: $DRRX FlaggingAfter breaking to higher ground a week ago on enormous volume, shares of DURECT CORP - NASDAQ:DRRX finds themselves consolidating the recent thrust in a Flag pattern on lower volume as we can observe from the Daily chart above.
In addition, DRRX is now trading above all of its important moving averages 20/50/200 DMA's, which from a technical perspective, is healthy as well as constructive.
Both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as we believe that its only a matter of time before the stock comes up-and-out of its Flag with its sights set on greener pastures.
Thus, investors/traders may want to put DRRX front-and-center on their radars as we're anticipating a potential move into the $1.40 - $1.60 zone (and potentially higher) should the stock pop out of its pattern within the days/weeks ahead.
****NOTE DURECT Corporation - NASDAQ:DRRX to Announce Second Quarter 2019 Financial Results on August 1, 2019 After Market Close ****
Harmonic Cypher Final Data from Robarts study coming September, in Spain. To learn more about TAEUS, click here .
Company ran by ex-GE executives. TAM is in the Billions of Dollars $$. Low float.
Recently broke long-term down trend. Daily, Weekly, Monthly charts #BULLISH. Fibonacci convergence at 618 fib (projection) into September time frame.
Follow me on twitter and instagram @ #VolatilityWatch
Disclaimer: I am long NDRA. This is not a recommendation to buy or sell. Please do your homework before investing.
Davita - now a BULL trend Technicals analysis WEEKLY
Davita broke a downtrend channel, and is now in a consolidation above the 200SMA. (Bull)
50SMA is now crossing above the 200SMA. (Bull)
OBV and RSI show divergence, as they have moved in oposite directions since early August. (Short). However... on a daily chart , we see a decent uptrend since early June.
Headlines / Fundamental
On July 10th:
President Donald Trump on Wednesday signed an executive order reimbursing for kidney transplants and reducing the reliance on the costly treatments at dialysis clinics.
Analyst fair value target price is $79. Meaning 38% undervalued .
Will they name JCPenney JCPenny?J. C. Penney Company, Inc. is an American department store chain with 865 locations. It is a micro-cap @$187million.
This upcoming earnings, this companies fate will be decided as the street awaits details of long-term plan.
If the stock remains below $1 for a period of 30 consecutive business days, they will face delisting from the NYSE market.
JCP August 0.50 straddle is priced for a move of 30% into the expected release of quarterly results before the bell on August 15th.
Analyst note:
B. Riley FBR lowers their JCP target to $0.60 from $1.30 as they believe that amid traffic/discounting pressure that has been impacting retail in general, there is downside risk to estimates.
QUOTIENT LTD - NASDAQ: $QTNT Works On Its BaseFor the better part of 2019, the shares of QUOTIENT LTD - NASDAQ: QTNT have found themselves range-bound trading within the $8 - $11 zone, while seemingly continuing to build and work on its long drawn base as is evidenced in the Daily chart above.
While further work is in order, QTNT remains in decent technical shape as the stock presently finds itself trading above all of its important moving averages 20/50/200 DMA's, which constitutes a healthy technical posture.
Additionally, when extending out to both the Weekly and Monthly time-frames, one can also observe that QTNT remains in fine shape as well. Therefore, we have a favorable technical picture across multiple time-frames, which bodes well.
Thus, while further work is required, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead for further clues/evidence that things may be about to pick-up. In particular, should QTNT be capable of going topside of the $9.75 level, we may just witness a rapid re-test of the $11 level and perhaps a move into the $12 - $14 zone down the road.
Bearish Butterfly SGEN has beat biotech averages significantly the past few months and has come to meet my $80 pt which also happens to make a bearish harmonic butterfly pattern. This could have a little more upside as it tests $80-81 but risk/reward would suggest a potential double top that can take this down quite a bit in a short amount of time. If I was short I would be looking to start a position.
According to the bearish setup SGEN should find 50 -618 retracement before next ER bringing SGEN down to around the $69 mark. As I have outlined in this setup, SGEN is still making higher lows on long-term chart and after retracing back to $69, should see continue uptrend to ~$84 (assuming another positive ER or catalyst).
Tip - Even if you rely mostly on company fundamentals, you should be aware of support/ resistance levels.
Please Follow, like, comment, and share so I can continue finding awesome trades. Thank you in advance >+)
Find me on Twitter or Instagram @VolatilityWatch
Disclosure: I do not own a position in SGEN. I may buy/sell within the next 72 hours. This is not a note to buy or sell, please do your homework before investing.
Corindus Vascular Robotics Inc. - NYSE: $CVRS ConsolidatingTECHNICAL
After breaking-out in early Spring (March) and subsequently digesting the move, CVRS broke-out once again last month (May) on enormous volume and now finds itself consolidating in a very constructive manner on lower volume as evidenced in the Daily chart above.
With the stock trading just beneath its 20 DMA, yet comfortably above both its 50 and 200 DMA's, the technical picture remains positive, while the recent move into northern territory is absorbed.
With that said, it now appears that it is only a matter of time before CVRS embarks on yet another potential leg higher.
Thus, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as the recent consolidation comes to a conclusion with a possible break for greener pastures and a move topside of 3.10 likely triggering its next meaningful advance.
HCA: HCA Healthcare Swing 6/7% (or long term investment)Happy Fourth of July, the most American way to celebrate is profiting off healthcare.
HCA Healthcare is the largest publicly traded healthcare system in the United States.
Has the scale to swallow non-profits and small scale hospitals across the United States.
Limits loss caused by Medicare and Medicaid patients by operating hospitals only in economically sound urban areas.
Focused on regions with higher median age such as Florida.
Combatting nursing shortage with a majority stake in Galen Nursing College.
Lots of debt but high cashflow limits the risk.
TA:
Weekly MACD Cross
Weekly 50ma
Fell in April due to UNH earnings concerns (nothing changed fundamentally)
Trading within a channel since December
Took an initial position April 23rd added more at 135.15. Looking to sell some at 144.00 and hold the rest for long term investment
